脐血CD_3AK细胞的制备、生物活性测定及临床应用初探

 目的　研究用脐血单个核细胞制备CD3 AK细胞的抗肿瘤作用 ,探讨肿瘤生物治疗近期疗效的免疫指标。方法　分离脐血单个核细胞 ,分别用IL 2和IL 2 +CD3 Ab诱导LAK和CD3AK细胞 ,并测其扩增数量和对K5 6 2细胞的杀伤活性 ;测定肿瘤患者用CD3 AK细胞治疗前后外周血单核细胞(PBMC)的NK杀伤活性。结果　脐血LAK细胞和脐血CD3 AK细胞均于培养后第 11天时扩增倍数最高 ,分别是培养前的 18倍、2 4倍 ,对K5 6 2的杀伤活性分别是培养前的 2 .6倍和 3.2倍 ;肿瘤患者输注CD3 AK细胞一疗程后 ,其PBMC的NK杀伤活性由 6 2 %升高到 82 % ,平均升高 32 %。结论　 (1)脐血单个核细胞是LAK细胞和CD3 AK细胞良好的前体细胞。 (2 )LAK和CD3 AK细胞的数量和杀伤能力在培养的第 11天时达高峰 ,而且CD3 AK细胞数量和杀伤活性明显优于LAK细胞。 (3)CD3 AK细胞输注能明显提高肿瘤患者PBMC的NK活性。 (4 )肿瘤病人PBMC的NK活性测定可望成为肿瘤生物治疗的一个近期疗效参数

Preparation and Bio-activive Assay of CD3AK Cell from Umbilical Blood

Objective Objective To study the anti tumor effect of CD 3AK cell prepared from umbilical blood, to explore the recent curative effect on tumor cases and seek better immune index for bio therapy.Methods IL 2 and IL 2 CD 3Ab was used to induce LAK cell and CD 3AK cell from umbilical blood mononuclear cells (UBMC). The expanding number and bio activity of LAK cell and CD 3AK cell were examined in different time after culture, the NK activity of peripheral blood mononuclear cells (PBMC) of 12 cases of malignant tumor patients were examined before and after CD 3AK cell adopting immune therapy as well.Results The number and bio activity(NK killing cancer K562)of LAK and CD 3AK cells reached their peaks on 11th day. The number of LAK and CD 3AK cells were 18 folds and 24 folds of the number before culture; the NK activity (killing K562 cell) of malignant tumor patient's PBMC had grown up to 82% from 62% by CD 3AK cell transfusing, the even rising ratio is 32%.Conclusion (1) The UBMC is a potential and better source of predecessor for LAK and CD 3AK. (2) The NK activity of LAK and CD 3AK cells from UBMC reached their peaks at 11th day after culture, and the NK activity of CD 3AK cell is much greater than that of LAK cell. (3) The NK activity of malignant tumor patient's PBMC can be obviously elevated by transfusing CD 3AK cell. (4) The test of NK activity of PBMC of malignant tumor patient may become a recent objective immune index for tumor bio therapy.